Double filtration plasmapheresis combined with daclizumab in the treatment for sensitized recipients of cadaver kidney transplantation
- VernacularTitle:双滤过法血浆分离联合达昔单抗预处理肾移植致敏受者的临床效果
- Author:
Hongfeng HUANG
;
Jianghua CHEN
;
Jianyong WU
- Publication Type:Journal Article
- Keywords:
Kidney transplantation;
Sensitized patien t;
Plasmapheresis;
Inducible therapy
- From:
Chinese Journal of Urology
1994;0(02):-
- CountryChina
- Language:Chinese
-
Abstract:
20% ) were assigned to 2 groups according to study intervention: group A ( n =72) receiving DFPP and group B ( n =41) as controls.Group A was subdivided into 2 groups:group A1 ( n =44) was treated by DFPP alone and group A2 ( n =28) was treated by DFPP plus Dac.The incidence rates of HAR,AR,adverse reaction,patie nt/kidney survival,kidney function were observed. All the patients obtained a fo llow-up ≥12 months. Results In 72 patients of group A ,the level of PRA decreased from (60.5?17.7)% to (19.3?11.2)%,with a mean of (41.2?16.9)% ( P 0.05),with 1 kidney-year survival of 94.4% in group A and 78.0 % in group B ( P 0.05);those of AR were 36.4% and 14.3%,respectively ( P 0.05).No difference in infection episodes an d adverse events between group A and PRA-negative recipients, the same as those between group A1 and A2. Conclusions DFPP can decrease the level of PRA significantly before transplantation by selectively eliminating the sensitive antibody,especially when combined with Dac,which can make sensiti zed recipients get the chance of transplanting and further reduce the incidence of AR.The patient/kidney survival rates of 1 year are satisfactory.Being well to lerated by the sensitized patients,treatment of DFPP combined with Dac is safe a nd effective.
